The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | How the treatment landscape of DLBCL is changing: R-CHOP vs pola-R-CHP
Jonathan W Friedberg, MD, MMSc, University of Rochester, Rochester, NY, shares some insights into how the treatment landscape of diffuse large B-cell lymphoma (DLBCL) is changing, drawing focus on the promise of pola-R-CHP. Dr Friedberg first highlights the heterogeneity of DLBCL, and then goes on to discuss the promise of pola-R-CHP compared to R-CHOP, based on findings from the POLARIX study (NCT03274492). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
